PREVENT Calculator (AHA PREVENT Calculator, PREVENT Score) for Cardiovascular Risk Assessment

The PREVENT calculator estimates the risk of a cardiovascular event over the next 10 and 30 years – reported separately for total CVD, ASCVD, and heart failure. It is based on the PREVENT model (“Predicting Risk of CVD EVENTs”), published in 2023 by the American Heart Association, which was developed as the successor to the previous Pooled Cohort Equations and is the first to systematically incorporate kidney function into the risk calculation.

Under Which Names Does This Model Appear in International Searches?

Anyone working with the PREVENT model will encounter different names for the same underlying tool depending on the source. The following mapping clarifies which term belongs to which part of the calculator:

These Inputs Enter the Calculation

Unlike older models, PREVENT requires not only the classic risk factors but also information on kidney function and current medication:

Three Numbers Instead of One: How to Read the Result

Unlike many older calculators, PREVENT does not output a single risk but three separate values, each for the 10- and the 30-year horizon:

• Total CVD: the sum of ASCVD and heart failure risk
• ASCVD: risk of heart attack or stroke due to atherosclerosis
• Heart failure: as a separate endpoint, because PREVENT is the first broadly validated model to estimate this risk independently

For interpreting the 10-year ASCVD value, the following classification, derived from the ACC/AHA cholesterol guideline, has become established:

• below 5%: low risk
• 5 to below 7.5%: borderline risk
• 7.5 to below 20%: intermediate risk
• 20% or higher: high risk

These thresholds are a prompt for discussing statin consideration, not an automatic treatment decision.

The “Heart Age” as an Illustrative Additional Measure

From the calculated risk, a heart age can be derived – the chronological age at which a person with average, optimal risk factors would have the same risk. When the heart age is well above the actual age, it makes the effect of risk factors such as smoking, high blood pressure, or reduced kidney function more tangible than a bare percentage can – a useful starting point for the physician consultation.

PREVENT and SCORE2 Compared

The obvious question from a German-speaking perspective: how does PREVENT relate to the SCORE2 model established in Europe?

In the German-speaking region, SCORE2 remains the ESC’s guideline-recommended model – transferring PREVENT risk thresholds to the European care setting has not yet been confirmed by the ESC. PREVENT nevertheless provides additional value, above all through its independent heart failure estimate and its inclusion of kidney function.

Data Base and Discrimination of the Model

PREVENT was developed in more than 6 million adults from 46 US datasets and externally validated in over 3.3 million additional individuals (Khan et al., Circulation 2024). Noteworthy aspects of its development:

• Separate coefficient sets for women and men, with no ethnicity factor in the model
• Accounting for the competing risk of noncardiovascular mortality
• External validation in a sample independent of the development population

The published discrimination (C-statistic) for total CVD risk was approximately 0.79 for women and 0.76 for men – a good to very good result for this type of model.

Why This Calculator Shows More Than a Single Number

The implementation on med-ffm.com differs from a pure single-number output in the following respects:

• Separate display of CVD, ASCVD, and heart failure risk instead of a single value
• 10- and 30-year perspective from the same input
• BMI entered directly or calculated from height and weight, eGFR entered directly or calculated from creatinine
• Runs entirely in the browser, with no storage of the entered values

What Makes Sense at Elevated Risk

Regardless of whether the result comes from PREVENT or SCORE2, similar evidence-based measures apply for risk reduction:

• Smoking cessation: produces a marked effect within as little as 12 months
• Lower LDL cholesterol: target below 70 mg/dL at high risk
• Lower blood pressure: target below 130/80 mm Hg
• Reduce weight: BMI below 25, directly risk-relevant in PREVENT
• Physical activity: at least 150 minutes of moderate activity per week
• Monitor kidney function: regular eGFR measurement, since this value enters the PREVENT risk calculation directly
• Drug therapy: statins, ACE inhibitors, or SGLT2 inhibitors depending on comorbidity

Where the Model Reaches Its Limits

• Developed and validated in US, not European, cohorts
• Not yet adopted by the ESC as the guideline-recommended model for Europe
• No regional calibration such as SCORE2 provides for European countries
• Not validated outside the age range of 30 to 79 years
• The 30-year estimate loses clinical value in patients over 60 years of age

The result should therefore always be interpreted in the physician consultation – in the German-speaking region, sensibly as a complement to SCORE2, not as its replacement.

Distinction From Similar-Sounding but Different Tools

Searches for PREVENT regularly turn up terms that denote other, sometimes fundamentally different, tools. For orientation:

How Often to Calculate, and What Follows From the Result?

As a rule of thumb: every 5 years at low risk, annually at high risk, and immediately when new risk factors appear, such as newly diagnosed impaired kidney function, new-onset diabetes, or a marked rise in blood pressure. After each calculation, three steps make sense from a medical standpoint: interpretation in a personal consultation, where appropriate compared with the SCORE2 result; documentation in the patient record system; and guideline-appropriate adjustment of therapy if required.